Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06954522 IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 1 , Formulation 2, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 2 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 2, Formulation 3, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 3 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 3, Formulation 1, and Formulation 2, under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 4 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 3, Formulation 2, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 5 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 1, Formulation 3, and Formulation 2 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively. |
| Sequence 6 | EXPERIMENTAL | Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as: Formulation 2, Formulation 1, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively. |
| Name | Type | Description |
|---|---|---|
| PF-06954522 IR (Formulation 1) | DRUG | Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth |
| PF-06954522 MR (Formulation 2) | DRUG | Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth. |
| PF-06954522 MR (Formulation 3) | DRUG | Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth |
Inclusion Criteria: * Male and female participants of non-childbearing potential aged 18 years or older who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiograms. * Body mass index of 16-32 kg/m...
PF-06954522 IR is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development. The drug is being studied in healthy participants to evaluate how different forms of the study medicine are taken up into the blood.
PF-06954522 IR is being studied in healthy participants as part of a Phase 1 clinical trial. The study aims to learn how different forms of the study medicine are taken up into the blood. It is not yet approved for any medical condition and remains in clinical development.
PF-06954522 IR is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
PF-06954522 IR is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, with results not yet reported.
PF-06954522 IR has one completed Phase 1 clinical trial, identified as NCT06393517. The study, titled "A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults," enrolled 23 participants in the United States.